7PA2 の概要
| エントリーDOI | 10.2210/pdb7pa2/pdb |
| 分子名称 | Parkinson disease protein 7, (3~{S})-~{N}-[5-[2-[(azanylidene-$l^{4}-azanylidene)amino]ethanoyl]-6,7-dihydro-4~{H}-[1,3]thiazolo[5,4-c]pyridin-2-yl]-1-(iminomethyl)pyrrolidine-3-carboxamide (3 entities in total) |
| 機能のキーワード | inhibitor, deglycase, unknown function |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 20495.72 |
| 構造登録者 | |
| 主引用文献 | Jia, Y.,Kim, R.Q.,Kooij, R.,Ovaa, H.,Sapmaz, A.,Geurink, P.P. Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput. J.Med.Chem., 65:13288-13304, 2022 Cited by PubMed Abstract: The multifunctional human Parkinson's disease protein 7 (PARK7/DJ1) is an attractive therapeutic target due to its link with early-onset Parkinson's disease, upregulation in various cancers, and contribution to chemoresistance. However, only a few compounds have been identified to bind PARK7 due to the lack of a dedicated chemical toolbox. We report the creation of such a toolbox and showcase the application of each of its components. The selective PARK7 submicromolar inhibitor with a cyanimide reactive group covalently modifies the active site Cys106. Installment of different dyes onto the inhibitor delivered two PARK7 probes. The Rhodamine110 probe provides a high-throughput screening compatible FP assay, showcased by screening a compound library (8000 molecules). The SulfoCy5-equipped probe is a valuable tool to assess the effect of PARK7 inhibitors in a cell lysate. Our work creates new possibilities to explore PARK7 function in a physiologically relevant setting and develop new and improved PARK7 inhibitors. PubMed: 36149939DOI: 10.1021/acs.jmedchem.2c01113 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.21 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






